Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.
about
Current prospects for the fluoroquinolones as first-line tuberculosis therapyAntituberculosis therapy for 2012 and beyondTreatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infectionStrategies for treating latent multiple-drug resistant tuberculosis: a decision analysisUniDrug-target: a computational tool to identify unique drug targets in pathogenic bacteriaHigh proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolatesInvestigation of the prevalence of female genital tract tuberculosis and its relation to female infertility:An observational analytical study.Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assayIncidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas.A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosisHigh proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.Moxifloxacin and gatifloxacin for initial therapy of tuberculosis: a meta-analysis of randomized clinical trials.Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised PatientsGuidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.Resistance to Second-Line Antituberculosis Drugs and Delay in Drug Susceptibility Testing among Multidrug-Resistant Tuberculosis Patients in Shanghai.Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of deathMicrocolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance.Update in tuberculosis 2009.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs.Levofloxacin for the treatment of respiratory tract infections.New treatment options for multidrug-resistant tuberculosis.Introduction to propensity scores.Quinolone-containing therapies in the eradication of Helicobacter pyloriComparative economic evaluation of home-based and hospital-based palliative care for terminal cancer patients.Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis.A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis.Atrial fibrillation after lung cancer surgery: incidence, severity, and risk factors.Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones.Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.Tuberculous prostate abscesses in an immunocompetent patient: A dramatic presentation of disseminated tuberculosis.Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.Effects of eating dinner alone on overweight in Japanese adolescents: a cross-sectional survey.
P2860
Q26823843-CAF09073-CF0B-43E8-9E3F-5FF68AEECDB7Q26829101-3AC021EB-4394-405E-AE13-1C7A8C0D941BQ28476640-C29D7630-52CE-46CF-967D-111CABA0B0D0Q28478920-F0D9C437-E3E1-4C1C-BE39-0B921D88A846Q28481491-1859110F-ED40-4B4B-B3FC-2BAF573449EFQ33798166-11925884-D19E-4654-BF00-4065EA788EEDQ34217573-A4BB0D78-8F39-4A65-8752-379EE387100AQ34741239-63F75DAD-3FBD-4287-859A-2F32648AF068Q35139691-F669B1D9-60FA-46AC-846A-B6C2F24573F1Q35155801-733436C2-F975-45A0-A3E8-F1A0929762BCQ35867806-2C616A32-41BF-41BB-95A5-2D02D5839E9AQ36281234-8E0BB096-E1CF-48D6-B287-5F8D3D211449Q36288667-20F6BE92-4249-4EDD-9D3B-80C59BA70D18Q36607348-5C3CF0B8-F5A2-42CE-9CA5-0E799AF93EB2Q36650622-9389C09A-492B-44D9-B98D-49B619CC7608Q36928273-E67A18AF-3069-4B83-88E5-AA23274995FFQ37023145-30FD9AB7-C0B5-4A1B-B13E-4E0E5BBE8921Q37177278-5D9C9065-291B-45BF-BA0C-CAE2508C1ABBQ37191156-3DA70CD7-1532-48BA-B4CE-09B1D0CE9660Q37249837-FFFD1063-EC42-4970-AD57-7674FCD45185Q37694565-09E5337E-1669-4381-A7CD-90A936F34394Q37694594-22F49131-683B-43F4-8C00-81CE165482A4Q37704062-773EC338-A252-43C4-9069-F09B8C04D299Q37799461-DC086F6F-F6AF-4AC6-8EDD-B0BA1012F392Q37810481-C76CA47B-B16A-4D69-A8FC-CA3A0C8B3293Q38010784-B44392AD-3630-4D89-B084-21F4AE0794CCQ38024041-BDCC5328-7A8A-4922-BF9A-D9C9BCD42318Q38217008-D07E901F-2F5B-40AB-B129-0D1F46010367Q38253054-2A2C86B4-F1A3-4937-A5CE-20E37297BCA6Q38970364-DCE4AB7E-BF7A-44E3-B393-52E4D8C03AD8Q38979626-3F75647D-5482-4E1A-A312-32D2D59F6F1FQ39646654-9880162F-FA0A-4C32-9BB7-936746A4FFBBQ40645861-D73077E0-2858-475A-8E1B-115034702316Q40665336-643E473C-A709-4973-8045-B2E0A1E578FAQ40688793-8B97502C-8122-4A3E-837F-630470AEEC16Q40957363-030833EF-BC1C-43B7-82B4-9FA19CF16605Q41009954-F99FAA27-FAB1-45A2-AE55-40D3312CBDC7Q41038046-209B8ED3-8251-4374-9242-0A1CE32F274EQ47426076-EFBEB9A2-76E8-4708-9C9C-CCDEE0D2976AQ48503044-FFCEB93B-B52D-41F6-9CBE-F3AAC0683E5D
P2860
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@en
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@nl
type
label
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@en
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@nl
prefLabel
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@en
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@nl
P2093
P2860
P1476
Fluoroquinolone resistance in ...... g of fluoroquinolone exposure.
@en
P2093
Amondrea Blackman
Ayumi Shintani
Carolyn May
Ed Mitchel
Fernanda Maruri
Jon Warkentin
Marie Griffin
Nancy Hooper
Rose A Devasia
Teresa Smith
P2860
P304
P356
10.1164/RCCM.200901-0146OC
P407
P577
2009-05-29T00:00:00Z